People living with HIV experience higher rates of mental health conditions, but adult attention-deficit/hyperactivity disorder (ADHD) has received little attention in the HIV literature. Traits associated with ADHD, together with social exclusion, adverse life events, stigma and healthcare access barriers, may increase vulnerability to HIV acquisition and complicate adherence to treatment and prevention. A similar pathway may apply to users of HIV pre-exposure prophylaxis (PrEP). Existing prevalence data for ADHD in people living with HIV are limited to two small studies, and no prevalence data are available for PrEP users. This protocol describes a study designed to estimate the prevalence of ADHD traits and to characterise associated sociodemographic, behavioural and clinical patterns in Swiss cohorts.
This is a multicentre cross-sectional survey nested within the Swiss HIV Cohort Study (SHCS) and the SwissPrEPared cohort. The study adopts a Critical ADHD Studies framework and was co-created and is co-led by individuals who bring lived experience in addition to academic and clinical expertise. The survey is embedded into routine clinical visits at participating cohort sites.
Recruitment will occur during routine cohort visits at participating SHCS and SwissPrEPared sites over a 12-month period. Eligible participants are adults attending these visits who are enrolled in the respective cohorts. Screening is intended to be implemented as part of standard follow-up encounters to facilitate integration with existing cohort procedures and data collection.
The screening instrument is the six-item Adult ADHD Self-Report Scale Screener (ASRS-5). A positive screen is defined in this protocol as a weighted ASRS-5 score of 14 or higher. In addition to the ASRS-5 items, the questionnaire includes three supplementary items to capture: the presence of ADHD-related traits in childhood before age 12; any previously established ADHD diagnosis; and whether the participant wishes to receive their score and/or a follow-up consultation with a psychologist or psychiatrist experienced in ADHD.
Screening responses will be linked to routinely collected cohort variables from SHCS and SwissPrEPared. Linked data will allow description and analysis of sociodemographic characteristics, behavioural variables (including substance use and sexual behaviour), clinical variables (including sexually transmitted infections), measures of depression and anxiety, adherence to HIV treatment and prevention, interest in and use of long-acting HIV treatment modalities, and gender identity and sexual orientation. The protocol specifies using these linked data to explore associations between ADHD traits and these outcomes.
The primary objective is to estimate the prevalence of a positive ASRS-5 screen in each cohort, reporting estimates with 95% Wilson score confidence intervals. Secondary objectives include between-cohort comparisons and examination of associations between screening-positive status and substance use, sexual behaviour, sexually transmitted infections, depression and anxiety, adherence to treatment or prevention, interest in long-acting HIV treatments, and gender identity and sexual orientation. The protocol also records prior ADHD diagnoses and childhood trait presence as descriptive outcomes.
The study targets a sample of 800 participants per cohort. This target was calculated to achieve a margin of error of approximately 3% for prevalence estimates. Analysis of the primary outcome will produce prevalence estimates with 95% Wilson score confidence intervals. Secondary analyses will assess associations between ADHD trait screening results and the linked cohort variables described above. Specific statistical methods for association analyses are not detailed beyond the planned comparisons and linkage to cohort data.
The project is nested within SHCS and SwissPrEPared and falls under their existing ethical approvals and the general data collection consent that participants provided on joining the cohorts. Participants who screen positive on the ASRS-5 and indicate a desire for follow-up will be offered a consultation with a psychologist or psychiatrist experienced in ADHD. Competing interests were declared as none by the authors. The protocol states that all relevant ethical guidelines were followed and institutional approvals and participant consents are in place through the parent cohorts.
Results will be made publicly available via the study website, published in peer-reviewed journals, and shared with participants and communities through lay summaries and cohort communication channels. The manuscript indicates that all data produced in the present work are contained within the manuscript. Funding sources declared include the Swiss HIV Cohort Study, the Swiss National Science Foundation, and Gilead Sciences Switzerland Sàrl. The preprint is available under a CC-BY-NC 4.0 International license.
The protocol paper reports study design, instruments, objectives, planned recruitment period and sample size target, linkage to cohort data, and planned participant follow-up options. Details such as the specific statistical models for secondary analyses, participating site list, and operational logistics for implementation at each centre were not reported in the source document.